List view / Grid view
CIRM grant will fund novel gene therapy that aims for single lifelong treatment of Friedreich’s ataxia, a progressive neuromuscular disorder; a second CIRM grant will advance efforts to leverage UC San Diego research on another rare disease
In this article, Drug Target Review’s Ria Kakkad shares some of the most recent progress in discovering a drug for COPD, a disease that remains a major challenge in the medical industry.
A study has suggested that a new vaccine could prevent fentanyl from entering the brain, after showing success in rats.
NIH researchers who intravenously delivered a cancer vaccine to mice report that it increased the number of T cells able to combat tumours.
UAB researchers have found that adding TBX20 to the reprogramming cocktail MGT 133 promoted cardiac reprograming.
A study has shown that mRNA delivered via lipid nanoparticles blocks multiple variants of SARS-CoV-2 from entering cells in mice.
Texas Biomed and The Access to Advanced Health Institute have been granted $3.5 million to initiate tuberculosis vaccine research, which includes using genetically diverse animal models.
A Boston University researcher has been granted funding for the development pre-clinical models to test potential Nipah virus vaccines.
A potential Zika virus vaccine, developed by deleting part of the Zika genome that codes for the viral shell, was effective and safe in mice.
7 September 2022 | By Sartorius
Watch this webinar to hear from Dr Yuansheng Yang as he introduces a CHO cell-based technology allowing simultaneous display and secretion of antibodies for accelerating the process of antibody development.
Scientists have found antibodies that summon virus-engulfing white blood cells may play an important role in protecting infants from cytomegalovirus.
A new study provides the possibility to evaluate the capacity of telomerase-positive human urine-derived stem cells to become a wide variety of other cell types.
Drug testing on advanced cell-based models such as organoids has gained in popularity, but significant technical hurdles remain that prevent further assay miniaturisation and higher assay throughput. Through the replacement of animal-derived basement membranes with wood-derived nanofibrillar cellulose hydrogel (NFC), Dr Tijmen Booij and Dr Christian Stirnimann from ETH Zurich,…
While the full potential of gene therapies continues to be realised, their successes in rare diseases promote them as a promising treatment modality. Dr Gaurav Shah, Chief Executive Officer of Rocket Pharmaceuticals discusses the future of gene therapies as well as the company’s progress in in vivo and ex vivo programmes.
In this article, Dr Mary Spellman, Chief Medical Officer and Senior Vice President of R&D at Castle Creek Biosciences, discusses how a versatile dual platform of ex vivo and in vivo gene therapy technologies is being utilised for the development of novel gene therapies for a broad range of rare…
